The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in <i>IDH</i>-mutant gliomas-Reference-Cited by-同舟云学术

The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas

Published:2023-12-09 Issue: Volume: Page:
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Albert Nathalie L¹^ORCID,Furtner Julia²,van den Bent Martin J³,Preusser Matthias⁴^ORCID

Affiliation:

1. Department of Nuclear Medicine, LMU Hospital, LMU Munich , Munich , Germany

2. Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University , Krems , Austria

3. The Brain Tumour Center at the Erasmus MC Cancer Institute , Rotterdam , The Netherlands

4. Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna , Austria

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

https://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noad240/54930500/noad240.pdf

Reference10 articles.

1. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma;Mellinghoff;N Engl J Med.,2023

2. Response assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas;Albert;Neuro Oncol,2016

3. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma;Harat;Nat Commun.,2023

4. Re-evaluation of the diagnostic performance of (11)C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas;Kim;Eur J Nucl Med Mol Imaging.,2019

5. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma;Mellinghoff;J Clin Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET imaging of gliomas: Status quo and quo vadis?;Neuro-Oncology;2024-07-06

2. IDH inhibition in gliomas: from preclinical models to clinical trials;Nature Reviews Neurology;2024-05-17